These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2501 related articles for article (PubMed ID: 7903405)

  • 1. Morphometric, DNA and PCNA in thin malignant melanomas.
    Björnhagen V; Månsson-Brahme E; Lindholm J; Mattsson A; Auer G
    Med Oncol Tumor Pharmacother; 1993; 10(3):87-94. PubMed ID: 7903405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
    Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
    Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary malignant melanoma of the skin. Relationships of nuclear DNA content, nuclear morphometric variables, Clark level and tumor thickness.
    Talve LA; Collan YU; Ekfors TO
    Anal Quant Cytol Histol; 1997 Feb; 19(1):62-74. PubMed ID: 9051188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative activity in Spitz's naevi compared with other melanocytic skin lesions.
    Hofmann-Wellenhof R; Rieger E; Smolle J; Kerl H
    Melanoma Res; 1993 Oct; 3(5):313-7. PubMed ID: 7904841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereological estimates of nuclear volume in thin malignant melanomas.
    Björnhagen V; Månsson-Brahme E; Lindholm J; Mattsson A; Sørensen FB
    Melanoma Res; 1998 Oct; 8(5):398-402. PubMed ID: 9835452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
    Takahashi H; Strutton GM; Parsons PG
    Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA ploidy in thin melanoma.
    Zardawi IM; Jarvis L; Hersey P; Francis L; Shaw H; Grace J
    Pathology; 1988 Jul; 20(3):243-6. PubMed ID: 3205595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.
    Tokuda Y; Mukai K; Matsuno Y; Furuya S; Shimosato Y; Takasaki Y; Saida T; Ishihara K
    Arch Dermatol Res; 1992; 284(6):319-23. PubMed ID: 1363460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of nuclear DNA and morphometry, and proliferating cell nuclear antigen in primary and metastatic malignant melanoma.
    Björnhagen V; Lindholm J; Auer G
    Scand J Plast Reconstr Surg Hand Surg; 1997 Jun; 31(2):109-18. PubMed ID: 9232695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative activity in the malignant cellular blue nevus.
    Pich A; Chiusa L; Margaria E; Aloi F
    Hum Pathol; 1993 Dec; 24(12):1323-9. PubMed ID: 7903955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study.
    Rieger E; Hofmann-Wellenhof R; Soyer HP; Kofler R; Cerroni L; Smolle J; Kerl H
    J Cutan Pathol; 1993 Jun; 20(3):229-36. PubMed ID: 8103531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA level, tumor thickness, and stereological estimates of nuclear volume in stage I cutaneous malignant melanomas. A comparative study with analysis of prognostic impact.
    Sørensen FB; Kristensen IB; Grymer F; Jakobsen A
    Am J Dermatopathol; 1991 Feb; 13(1):11-9. PubMed ID: 2003643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear morphometry of MIB-1 positive and negative tumor cells in primary and metastatic malignant melanoma of the skin.
    Karbowniczek M; Chosia M; Domagała W
    Pol J Pathol; 1999; 50(4):235-41. PubMed ID: 10721263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate.
    Tu P; Miyauchi S; Miki Y
    Am J Dermatopathol; 1993 Aug; 15(4):311-4. PubMed ID: 8105711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.
    Sparrow LE; English DR; Taran JM; Heenan PJ
    Am J Dermatopathol; 1998 Feb; 20(1):12-6. PubMed ID: 9504663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-index and stereological estimation of nuclear volume in primary and metastatic malignant melanomas: a comparative study with analysis of heterogeneity.
    Sørensen FB; Kristensen IB; Grymer F; Jakobsen A
    APMIS; 1990 Jan; 98(1):61-70. PubMed ID: 2302343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen.
    Niemann TH; Argenyi ZB
    Am J Dermatopathol; 1993 Oct; 15(5):441-5. PubMed ID: 7902020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of proliferation-associated proteins (proliferating cell nuclear antigen and Ki-67 antigen) in Bowen's disease.
    Baum HP; Meurer I; Unteregger G
    Br J Dermatol; 1994 Aug; 131(2):231-6. PubMed ID: 7917988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy.
    Corsetti RL; Allen HM; Wanebo HJ
    Ann Surg Oncol; 2000 Jul; 7(6):456-60. PubMed ID: 10894142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proliferative fraction in lymph nodes: a comparison of proliferating cell nuclear antigen morphometry to flow cytometry.
    Krauss JS; Pantazis CG; Chandler FW
    Ann Clin Lab Sci; 1992; 22(3):189-96. PubMed ID: 1354428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 126.